SCHEMBL10163558

SCHEMBL10163558

Cn1c(=O)oc2ccc(CNC(=O)c3cc(C(=O)NCc4cccc(C(C)(F)F)n4)n4nccc4n3)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLS O94925 2/20 0.37
MMP13 P45452 2/20 0.36
ADAMTS4 O75173 1/20 0.36
MMP3 P08254 1/20 0.36
MMP8 P22894 1/20 0.36
MMP12 P39900 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
PDE10A Q9Y233 1/20 0.35
METTL3 Q86U44 6/20 0.34
METTL14 Q9HCE5 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8228914 0.95 GLS (0.43) GLSMMP13ADAMTS4MMP3MMP8
SCHEMBL10163598 0.89 ADAMTS4 (0.36) GLSMMP13ADAMTS4MMP3MMP8
SCHEMBL10163543 0.88 MMP13 (0.42) GLSMMP13ADAMTS4MMP3KDM4E
SCHEMBL10163587 0.87 MMP13 (0.37) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8225381 0.87 HPGD (0.49) KDM4EALDH1A1HPGDHSD17B10PDE10A
SCHEMBL8219976 0.86 MMP13 (0.37) GLSMMP13ADAMTS4MMP3MMP8
SCHEMBL8226340 0.86 MMP13 (0.37) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8229567 0.86 ROCK2 (0.42) GLSMMP13ADAMTS4MMP3MMP8
SCHEMBL10162869 0.86 ROCK2 (0.41) GLSLMNATP53
SCHEMBL8227563 0.85 CDK2 (0.37) MMP13ADAMTS4MMP3MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 GLS 1120/4885MMP13 1/4885ADAMTS4 38/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 GLS 1120/4885MMP13 1/4885ADAMTS4 38/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 GLS 1120/4885MMP13 1/4885ADAMTS4 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.